Antiglycolytic drug with limited efficacy.1,2 Mito-lonidamine (2361564-49-8) is lonidamine conjugated to a triphenylphosphonium moiety via a decyl-linker which is an effective mitochondria-targeting group.3 Mito-lonidamine was shown to be100-fold more potent than lonidamine. It is a tumor-selective inhibitor of oxidative phosphorylation inhibiting mitochondrial bioenergetics in lung cancer cells and suppressing lung cancer cell viability, growth, progression and metastasis of lung cancer xenografts in mice.3
* VAT and and shipping costs not included. Errors and price changes excepted
